growth%20hormone%20deficiency%20(pediatric)
GROWTH HORMONE DEFICIENCY (PEDIATRIC)
Growth hormone deficiency is a congenital or an acquired growth hormone axis disruption in the higher brain, hypothalamus or pituitary which results in short stature.
It may occur at any age.
Short stature is often the only feature present in patients with growth hormone deficiency and other causes of subnormal growth rate.
Etiology may be congenital conditions (eg defective pituitary development that leads to pituitary aplasia, empty sella, encephalocele, midline defects) or acquired conditions (eg tumors of the hypothalamic-pituitary region, cranial irradiation, infiltrative disease).

Monitoring

Prescribed End Points

  • IGF-I in normal range for age and sex
    • Increase dose if IGF-I is low and decrease dose if IGF-I is above normal range
  • Improvement in blood lipid profile, body composition (change in lipolysis and increase in bone density) and waist-hip ratio
  • Increased muscle strength and exercise performance
  • Reduction in cardiovascular risk factors

Patient Monitoring

  • Close follow-up care with an endocrinologist is recommended to monitor the child’s growth and to adjust the dose of growth hormone (GH) therapy
  • Initial follow-up should be every month; thereafter, visits may be less frequent but should be at least 2x/year
  • Children on growth hormone (GH) therapy should be evaluated every 3-6 months, with increases in height and height velocity as the most important indicators of response
  • Monitor thyroid function every 6 months
  • Bone age, HbA1c levels, and adrenal function should also be assessed regularly
  • Monitor patients for hyperglycemia because growth hormone (GH) may reduce insulin sensitivity; patients with diabetes mellitus (DM) may need to adjust their insulin during treatment
    • Serum IGF-1 and IGFBP-3 levels should be obtained annually to effectively monitor treatment adherence & response
    • Dose should be reduced if serum IGF-1 levels increase above the normal range
  • Funduscopic examination is recommended at the start of therapy and periodically during the course of treatment
  • Growth hormone (GH) treatment is meant to be a replacement therapy and can only be expected to make short children grow at a normal growth rate
  • Most children treated with growth hormone (GH) replacement reach a normal adult height
    • Child’s growth usually increases most during the 1st years, with an average increase of 8-10 cm/year
    • Growth rate slows down over the next several years
  • Re-evaluation should be done once patient completed
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Apr 2016
Among adolescents who have only received diphtheria, tetanus toxoids, acellular pertussis (DTaP) vaccines in childhood, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine provides moderate protection against pertussis during the first year and then wanes rapidly thereafter.
26 Jul 2007
Despite the prevalence of corticosteroid use in infants with bronchiolitis, data on its efficacy is insufficient. In this study, oral dexamethasone was compared with placebo in the treatment of bronchiolitis.